Details for New Drug Application (NDA): 205098
✉ Email this page to a colleague
▶ Start for $100
Remove trial restrictions
The generic ingredient in VARITHENA is polidocanol. Two suppliers are listed for this compound. Additional details are available on the polidocanol profile page.
Summary for 205098
Tradename: | VARITHENA |
Applicant: | Provensis |
Ingredient: | polidocanol |
Patents: | 5 |
Formulation / Manufacturing: | see details |
DrugPatentWatch® Estimated Generic Entry Opportunity Date for 205098
Generic Entry Date for 205098*:
Constraining patent/regulatory exclusivity:
Dosage:
SOLUTION;INTRAVENOUS |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Suppliers and Packaging for NDA: 205098
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
VARITHENA | polidocanol | SOLUTION;INTRAVENOUS | 205098 | NDA | Biocompatibles, Inc. | 60635-107 | 60635-107-01 | 1 POUCH in 1 CARTON (60635-107-01) / 1 KIT in 1 POUCH * 7.75 mL in 1 CANISTER (60635-007-01) * 303 mL in 1 CANISTER |
VARITHENA | polidocanol | SOLUTION;INTRAVENOUS | 205098 | NDA | Biocompatibles, Inc. | 60635-111 | 60635-111-01 | 1 CARTON in 1 PACKAGE (60635-111-01) / 1 POUCH in 1 CARTON / 1 KIT in 1 POUCH * 7.75 mL in 1 CANISTER (60635-007-01) * 303 mL in 1 CANISTER |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION;INTRAVENOUS | Strength | 180MG/18ML (10MG/ML) | ||||
Approval Date: | Nov 25, 2013 | TE: | RLD: | Yes | |||||
Patent: | ⤷ Sign Up | Patent Expiration: | Jul 19, 2022 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
Patent: | ⤷ Sign Up | Patent Expiration: | Nov 17, 2024 | Product Flag? | Y | Substance Flag? | Y | Delist Request? | |
Patented Use: | A METHOD OF INTRAVENOUS INJECTION USING ULTRASOUND GUIDANCE, ADMINISTERED VIA A SINGLE CANNULA INTO THE LUMEN OF THE TARGET INCOMPETENT TRUNK VEINS OR BY DIRECT INJECTION INTO VARICOSITIES | ||||||||
Patent: | ⤷ Sign Up | Patent Expiration: | Nov 19, 2027 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
Patented Use: | A METHOD OF GENERATING AN INJECTABLE FOAM OF CONTROLLED DENSITY AND BUBBLE SIZE |
Expired US Patents for NDA 205098
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Provensis | VARITHENA | polidocanol | SOLUTION;INTRAVENOUS | 205098-001 | Nov 25, 2013 | ⤷ Sign Up | ⤷ Sign Up |
Provensis | VARITHENA | polidocanol | SOLUTION;INTRAVENOUS | 205098-001 | Nov 25, 2013 | ⤷ Sign Up | ⤷ Sign Up |
Provensis | VARITHENA | polidocanol | SOLUTION;INTRAVENOUS | 205098-001 | Nov 25, 2013 | ⤷ Sign Up | ⤷ Sign Up |
Provensis | VARITHENA | polidocanol | SOLUTION;INTRAVENOUS | 205098-001 | Nov 25, 2013 | ⤷ Sign Up | ⤷ Sign Up |
Provensis | VARITHENA | polidocanol | SOLUTION;INTRAVENOUS | 205098-001 | Nov 25, 2013 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription